- Title
- Phase 2 Randomized Study of p53 Antisense Oligonucleotide (Cenersen) Plus Idarubicin With or Without Cytarabine in Refractory and Relapsed Acute Myeloid Leukemia
- Creators
- Jorge CORTES - MD Anderson Cancer Center, Houston, Texas, United StatesHagop KANTARJIAN - MD Anderson Cancer Center, Houston, Texas, United StatesEdward D BALL - University of California San Diego, La Jolla, California, United StatesJohn DIPERSIO - Washington University, St. Louis, Missouri, United StatesJonathan E KOLITZ - North Shore University Hospital, Manhasset, New York, United StatesHugo F FERNANDEZ - University of Miami, Miami, Florida, United StatesMark GOODMAN - University of Miami, Miami, Florida, United StatesGautam BORTHAKUR - MD Anderson Cancer Center, Houston, Texas, United StatesMaria R BAER - Roswell Park Cancer Institute, Buffalo, New York, United StatesMeir WETZLER - Roswell Park Cancer Institute, Buffalo, New York, United States
- Publication Details
- Cancer, Vol.118(2), pp.418-427
- Publisher
- Wiley-Blackwell; Hoboken, NJ
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- PMID
- 21717444
- Record Identifier
- 991031576895402976
Journal article
Phase 2 Randomized Study of p53 Antisense Oligonucleotide (Cenersen) Plus Idarubicin With or Without Cytarabine in Refractory and Relapsed Acute Myeloid Leukemia
Cancer, Vol.118(2), pp.418-427
2012
PMID: 21717444
Metrics
12 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.25 Molecular & Cell Biology - Cancer, Autophagy & Apoptosis
- 1.25.656 P53
- Web Of Science research areas
- Oncology
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites